DK2809683T3 - ANTI-phospholipase D 4 ANTIBODY - Google Patents

ANTI-phospholipase D 4 ANTIBODY Download PDF

Info

Publication number
DK2809683T3
DK2809683T3 DK13705843.4T DK13705843T DK2809683T3 DK 2809683 T3 DK2809683 T3 DK 2809683T3 DK 13705843 T DK13705843 T DK 13705843T DK 2809683 T3 DK2809683 T3 DK 2809683T3
Authority
DK
Denmark
Prior art keywords
sequence
antibody
pld4
ser
cell
Prior art date
Application number
DK13705843.4T
Other languages
Danish (da)
English (en)
Inventor
Minkwon Cho
Tomohide Yamazaki
Mayuki Endo
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2809683(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Application granted granted Critical
Publication of DK2809683T3 publication Critical patent/DK2809683T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK13705843.4T 2012-01-31 2013-01-31 ANTI-phospholipase D 4 ANTIBODY DK2809683T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012018266 2012-01-31
PCT/JP2013/052781 WO2013115410A2 (en) 2012-01-31 2013-01-31 Anti-phospholipase d4 antibody

Publications (1)

Publication Number Publication Date
DK2809683T3 true DK2809683T3 (en) 2018-12-10

Family

ID=47748721

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13705843.4T DK2809683T3 (en) 2012-01-31 2013-01-31 ANTI-phospholipase D 4 ANTIBODY
DK18188036.0T DK3431504T3 (da) 2012-01-31 2013-01-31 Antiphospholipase d4-antistof

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18188036.0T DK3431504T3 (da) 2012-01-31 2013-01-31 Antiphospholipase d4-antistof

Country Status (15)

Country Link
US (2) US9944715B2 (enExample)
EP (2) EP3431504B1 (enExample)
JP (4) JP6118345B2 (enExample)
KR (1) KR102098413B1 (enExample)
CN (2) CN104284903B (enExample)
AU (2) AU2013215886B2 (enExample)
CA (1) CA2863009C (enExample)
DK (2) DK2809683T3 (enExample)
ES (2) ES2873035T3 (enExample)
HU (2) HUE054362T2 (enExample)
IL (1) IL233794B (enExample)
PL (2) PL3431504T3 (enExample)
PT (1) PT2809683T (enExample)
TR (1) TR201819828T4 (enExample)
WO (1) WO2013115410A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2863009C (en) * 2012-01-31 2020-07-07 Sbi Biotech Co., Ltd. Anti-phospholipase d4 antibody
AU2014297217B2 (en) * 2013-07-30 2020-01-16 Sbi Biotech Co., Ltd. Medicament comprising anti-phospholipase D4 antibody
US10294301B2 (en) * 2013-12-24 2019-05-21 Astellas Pharma Inc. Anti-human BDCA-2 antibody
JP2019509759A (ja) 2016-01-14 2019-04-11 ビーピーエス バイオサイエンス、インク.Bps Bioscience, Inc. 抗pd−1抗体及びその使用
BR112018067951A2 (pt) * 2016-03-10 2019-02-05 Viela Bio, Inc. moléculas que se ligam a ilt7 e métodos de uso destas
CN105624325B (zh) * 2016-03-31 2019-06-11 北京泱深生物信息技术有限公司 肺腺癌的诊治标记物
HUE054037T2 (hu) * 2017-10-14 2021-08-30 Abbvie Inc CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra
CN110042123B (zh) * 2019-01-07 2023-01-17 西北农林科技大学 一种通过诱导表达zfp57提高牛体细胞克隆效率的方法
WO2025085746A1 (en) * 2023-10-18 2025-04-24 Immunorx Pharma Inc. Humanized anti-s100a9 antibody
CN119120388A (zh) * 2024-10-22 2024-12-13 江苏亲科生物研究中心有限公司 一种pdpfl单克隆抗体及其试剂盒的制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098015B2 (en) * 1999-06-11 2006-08-29 Millennium Pharmaceuticals, Inc. 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
MXPA05005925A (es) 2002-12-02 2006-02-08 Abgenix Inc Anticuerpos dirigidos a la fosfolipasa a2 y sus usos.
EP1674111B1 (en) * 2004-07-09 2010-11-03 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
CA2863009C (en) 2012-01-31 2020-07-07 Sbi Biotech Co., Ltd. Anti-phospholipase d4 antibody
AU2014297217B2 (en) * 2013-07-30 2020-01-16 Sbi Biotech Co., Ltd. Medicament comprising anti-phospholipase D4 antibody

Also Published As

Publication number Publication date
ES2873035T3 (es) 2021-11-03
PL2809683T3 (pl) 2019-03-29
JP7244102B2 (ja) 2023-03-22
AU2013215886A1 (en) 2014-08-14
EP3431504B1 (en) 2021-03-24
JP2019048874A (ja) 2019-03-28
BR112014018539A2 (enExample) 2017-06-20
KR20140126337A (ko) 2014-10-30
ES2694165T3 (es) 2018-12-18
WO2013115410A3 (en) 2013-09-26
TR201819828T4 (tr) 2019-01-21
EP2809683A2 (en) 2014-12-10
AU2018200934B2 (en) 2019-09-12
BR112014018539A8 (pt) 2017-07-11
JP6118345B2 (ja) 2017-04-19
HUE041552T2 (hu) 2019-05-28
WO2013115410A2 (en) 2013-08-08
JP2015508056A (ja) 2015-03-16
JP2017155045A (ja) 2017-09-07
EP3431504A1 (en) 2019-01-23
EP2809683B1 (en) 2018-10-03
US9944715B2 (en) 2018-04-17
CN104284903B (zh) 2020-10-09
CN112442128A (zh) 2021-03-05
PT2809683T (pt) 2019-01-17
CA2863009C (en) 2020-07-07
CA2863009A1 (en) 2013-08-08
US20150044226A1 (en) 2015-02-12
JP6830471B2 (ja) 2021-02-17
US10336834B2 (en) 2019-07-02
JP2021019630A (ja) 2021-02-18
AU2018200934A1 (en) 2018-03-01
KR102098413B1 (ko) 2020-04-07
US20180258185A1 (en) 2018-09-13
HUE054362T2 (hu) 2021-09-28
PL3431504T3 (pl) 2021-10-18
IL233794B (en) 2021-04-29
CN104284903A (zh) 2015-01-14
DK3431504T3 (da) 2021-06-28
IL233794A0 (en) 2014-09-30
CN112442128B (zh) 2024-05-17
AU2013215886B2 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
DK2809683T3 (en) ANTI-phospholipase D 4 ANTIBODY
JP6491701B2 (ja) 新規モジュレーターと使用の方法
HK1218126A1 (zh) 抗ilt7抗体
WO2012031273A9 (en) Novel modulators and methods of use
KR20140018837A (ko) 노텀 단백질 조절 인자 및 사용 방법
KR102367760B1 (ko) 항-포스포리파아제 d4 항체를 포함하는 의약
Nishida et al. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions
HK40039509A (en) Anti-phospholipase d4 antibody
HK40039509B (zh) 抗磷脂酶d4抗体
CN107108736B (zh) Trail受体结合剂及其用途
BR112014018539B1 (pt) Método de preparar um hibridoma que produz um anticorpo monoclonal, hibridoma, anticorpo monoclonal ou um fragmento contendo uma região de ligação ao antígeno do mesmo, método de preparar um anticorpo monoclonal, método ex vivo de detectar uma célula dendrítica plasmacitóide, reagente para a detecção de uma célula dendrítica plasmacitóide, método ex vivo de suprimir uma atividade de uma célula dendrítica plasmacitóide e agente para suprimir uma atividade de uma célula dendrítica plasmacitóide
HK1234068A (en) Novel modulators and methods of use
HK1234068A1 (en) Novel modulators and methods of use
HK1188797A (en) Anti-ilt7 antibody